Zepp Health Corp: Form 20-F for the period ended Dec 31, 2017
Filed with the SEC on Apr 27, 2018 and accepted by EDGAR at Apr 27, 2018, 12:41 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2017-01-01 to 2017-12-31 | CNY 2.05bn | us-gaap:Revenues |
| Cost of revenue | 12 months2017-01-01 to 2017-12-31 | $238.9m | us-gaap:CostOfRevenue |
| Gross profit | 12 months2017-01-01 to 2017-12-31 | $76.0m | us-gaap:GrossProfit |
| Research and development | 12 months2017-01-01 to 2017-12-31 | $23.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2017-01-01 to 2017-12-31 | $28.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2017-01-01 to 2017-12-31 | $4.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2017-01-01 to 2017-12-31 | $25.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | $0.10 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2017-01-01 to 2017-12-31 | $0.10 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2017-01-01 to 2017-12-31 | 76,291,901 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | $36.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | $3.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-12-31 | $56.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-12-31 | $199.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $225.2m | us-gaap:Assets |
| Current liabilities | At period end2017-12-31 | $134.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-12-31 | $136.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-12-31 | $34.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-18-009509. Last ingested by Listed: Nov 5, 2026, 14:06 ET. Listed shows no prices and gives no investment advice.